Coalition Letter to Sens. Alexander and Murray regarding the Prescription Drug User Fee Act (PDUFA) Reauthorization

Christina Karonis Radio

prescription drugs; generic drugs; biosimilars; user fee agreements; PDUFA; prescription drug user fee act; GDUFA; generic drug user fee act; BsUFA; biosimilar user fee act; user fees; CSRxP; Campaign for Sustainable Drug Pricing; drug pricing; FDA; Food and Drug Administration; anti-competitive; CREATES Act; orphan drugs; orphan drug incentives

Fri, 04/28/2017 - 11:49 AM EDT

Wed, 09/25/2019 - 10:28 AM EDT

2

coalition_letter_to_senators_alexander_murray_regarding_pdufa_reauthorization_2017.pdf

{"Author":"Christina Karonis Radio","CreationDate":"2017-04-28T11:49:04-04:00","Creator":"Microsoft\u00ae Word 2013","Keywords":"prescription drugs; generic drugs; biosimilars; user fee agreements; PDUFA; prescription drug user fee act; GDUFA; generic drug user fee act; BsUFA; biosimilar user fee act; user fees; CSRxP; Campaign for Sustainable Drug Pricing; drug pricing; FDA; Food and Drug Administration; anti-competitive; CREATES Act; orphan drugs; orphan drug incentives","ModDate":"2019-09-25T10:28:00-04:00","Producer":"Microsoft\u00ae Word 2013","Title":"Coalition Letter to Sens. Alexander and Murray regarding the Prescription Drug User Fee Act (PDUFA) Reauthorization","Pages":2,"dc:format":"application\/pdf","dc:creator":"Christina Karonis Radio","dc:title":"Coalition Letter to Sens. Alexander and Murray regarding the Prescription Drug User Fee Act (PDUFA) Reauthorization","dc:subject":["prescription drugs","generic drugs","biosimilars","user fee agreements","PDUFA","prescription drug user fee act","GDUFA","generic drug user fee act","BsUFA","biosimilar user fee act","user fees","CSRxP","Campaign for Sustainable Drug Pricing","drug pricing","FDA","Food and Drug Administration","anti-competitive","CREATES Act","orphan drugs","orphan drug incentives"],"xmp:createdate":"2017-04-28T11:49:04-04:00","xmp:creatortool":"Microsoft\u00ae Word 2013","xmp:modifydate":"2019-09-25T10:28-04:00","xmp:metadatadate":"2019-09-25T10:28-04:00","pdf:producer":"Microsoft\u00ae Word 2013","pdf:keywords":"prescription drugs; generic drugs; biosimilars; user fee agreements; PDUFA; prescription drug user fee act; GDUFA; generic drug user fee act; BsUFA; biosimilar user fee act; user fees; CSRxP; Campaign for Sustainable Drug Pricing; drug pricing; FDA; Food and Drug Administration; anti-competitive; CREATES Act; orphan drugs; orphan drug incentives","xmpmm:documentid":"uuid:1c148b46-5208-4402-8666-0233e2bfed21","xmpmm:instanceid":"uuid:22d85cea-0306-4a0d-b3b2-f969bec36934"}

2017